clinical trial · NCT06903702
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Acute Myeloid LeukemiaAzacitidine (AZA)VenetoclaxAllogeneic hematopoietic stem cell transplantation
brief summary
The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
started
Aug 4, 2026
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Jul 9, 2026
official title
A Randomized, Multicenter, Phase II Study of Maintenance Azacitidine and Venetoclax Versus an Allogeneic Stem Cell Transplant in Older Patients (65 Years and Older) With Acute Myeloid Leukemia Who Achieve an MRD Negative Complete Remission After Induction With Azacitidine and Venetoclax
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol